Related coverage linked through entity extraction aliases.
Aug 22, 2026
HRSA announced a revised 340B Rebate Model Pilot Program effective January 1, 2027, letting manufacturers use rebates instead of upfront discounts. Rebate plans are due August 24, 2026.
Aug 09, 2026
The FDA approved Moderna's mFlusiva, the first mRNA-based flu vaccine, for adults 50 and older. Full approval covers ages 50-64; accelerated approval covers 65+. Moderna expects availability later this year, pending CDC recommendation.
Aug 05, 2026
Federal courts are weighing whether the April 2026 marijuana rescheduling order was lawful. MMJ argues the Attorney General skipped required rulemaking; DEA testimony flagged omitted diversion analysis. A stay motion is pending.
Aug 04, 2026
FDA final guidance sets standards for psychedelic clinical trials. Federal agencies and states are advancing psilocybin and ibogaine research, and Eli Lilly is acquiring AtaiBeckley for $2.8 billion.
Jul 23, 2026
The FDA has finalized the revocation of Orange B and proposed revoking Citrus Red No. 2, while exercising enforcement discretion to permit ‘no artificial colors’ claims on foods that avoid petroleum‑based dyes. The actions are part of a broader initiative to phase out synthetic dyes and fast‑track natural alternatives.
Jul 22, 2026
The FDA proposes to remove three GLP-1 drugs from the bulk compounding list as adverse events near 2,000 and Senator Tom Cotton demands a probe into Chinese APIs in compounded meds. Shortages have largely resolved, but safety and innovation concerns persist.
Jun 21, 2026
The FDA now allows "no artificial colors" labeling claims for foods without FD&C-certified synthetic colors, part of federal efforts to transition away from petroleum-based dyes. The agency approved beetroot red and expanded spirulina extract uses while initiating a safety review of preservative BHA.
Jun 19, 2026
An FDA advisory panel unanimously recommended approval of Moderna's mRNA flu vaccine mFlusiva for adults 50 and older. The vaccine showed a 27% reduction in flu cases versus a standard shot. A final FDA decision is expected by early August.
Jun 16, 2026
HHS and CMS issued a proposed rule to codify the Medicare Drug Price Negotiation Program, largely formalizing existing guidance. The rule includes new provisions, such as clarifications for new drug formulations. The proposal is now open for public comment.
May 18, 2026
The FDA pulled back publication of several studies on COVID-19 and shingles vaccines. The blocked studies involved millions of patient records, and two COVID-19 papers were withdrawn in October 2025.
May 02, 2026
The Fifth Circuit reinstated an in-person dispensing requirement for mifepristone, blocking telemedicine prescriptions. The ruling came after a federal judge paused Louisiana's lawsuit pending the FDA's safety review of the abortion medication.
Apr 25, 2026
US health policy activity this week included HHS FY 2027 budget hearings, a House review of Medicare fraud and bipartisan discussion of PBM reform. President Trump also issued an executive order on mental illness treatments, and CMS and FDA announced the RAPID pathway.
Apr 23, 2026
The acting director of the CDC delayed publication of a report showing the COVID-19 vaccine cut emergency department visits and hospitalizations for healthy adults last winter by about half. The Department of Health and Human Services did not immediately respond to request for comment.
Apr 22, 2026
mRNA cancer vaccines showed promising pancreatic cancer trial results and boosted tumor-fighting drugs in other research. U.S. officials canceled $500 million in vaccine funding, while the NCI is backing a $200 million cancer vaccine partnership.
Apr 15, 2026
The FDA has expanded animal drug options for New World screwworm through conditional approvals and emergency use authorizations. The agency lists products for cattle, dogs and cats and says its guidance page will be updated as more drugs move through the system.
Mar 13, 2026
NIH funded dramatically fewer research grants in 2025, with funding rates dropping from 27% to 20% for established investigators and from 26% to 19% for early-career researchers, according to newly released agency data.
Mar 07, 2026
Dr. Vinay Prasad, director of the FDA's Center for Biologics Evaluation and Research, will depart the agency by the end of April to return to an academic role at the University of California San Francisco.
Feb 25, 2026
The CDC's vaccine advisory committee meeting scheduled for February 25-27 has been canceled and rescheduled for March 18-19, as medical groups challenge the panel's composition and policies under Health Secretary Robert F. Kennedy Jr.
Feb 24, 2026
Ralph Abraham resigned as CDC principal deputy director after less than two months, leaving the agency's top two positions vacant. The departure is part of broader HHS leadership changes under Secretary Robert F. Kennedy Jr.
Feb 19, 2026
The FDA has reversed its earlier refusal and will now review Moderna's mRNA-1010 seasonal influenza vaccine application, setting an August 5, 2026 review deadline after the company proposed a revised regulatory approach based on age groups.
